Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism
Benzinga Newsdesk 5 days ago
BiotechGeneralNews
Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D., Professor of Medicine at Albany Medical College, during Kidney Week 2026, the annual meeting of the American Society of Nephrology.